Follow
Kagan Atikeler
Kagan Atikeler
Verified email at uu.nl
Title
Cited by
Cited by
Year
A review of rare disease policies and orphan drug reimbursement systems in 12 Eurasian countries
M Czech, A Baran-Kooiker, K Atikeler, M Demirtshyan, K Gaitova, ...
Frontiers in public health 7, 416, 2020
942020
Türkiye özel ve kamu sağlik sigortaciliği prim/hasarsağlik harcamasi değerlendirmesi
G Koçkaya, K Atikeler, F YENİLMEZ
Sosyal Güvence, 82-101, 2016
192016
Comparison of pharmaceutical pricing and reimbursement systems in Turkey and certain EU countries
EK Atikeler, G Özçelikay
SpringerPlus 5, 1-8, 2016
152016
Cost effectiveness and economic value of obesity surgery for Turkey (CEVOS-T)
G Koçkaya, FB Yenilmez, G Ergin, K Atikeler, M Tatar
Obesity Medicine 1, 33-37, 2016
82016
Access to medicines in Turkey: Evaluation of the process of medicines brought from abroad
EK Atikeler, HGMB Leufkens, W Goettsch
International Journal of Technology Assessment in Health Care 36 (6), 585-591, 2020
52020
Operational cost of obesity surgery in Turkey
G Koçkaya, FB Yenilmez, G Ergin, K Atikeler, M Tatar, MM Özmen, ...
Eur J Endosc Laparosc Surg 1 (2), 78-83, 2014
52014
Cost Evaluation of Inhaler Therapies Used in Respiratory Diseases: 1998--2015 Period in Turkey
B Bayar, NU Kutkan, EŞ Yılmaz, Ç Tolun, E Doğan, EK Atikeler, EH Vural, ...
Value in health regional issues 13, 31-38, 2017
32017
What is The Level of Transparency in Health Technology Assessment Process in Hungary, Romania and Turkey?
M Subtirelu, OC Mic, D Daneasa, M Csanadi, K Atikeler, E Dogan, ...
Value in Health 19 (7), A634-A635, 2016
32016
Comparison of pharmaceutical pricing and reimbursement systems in turkey and certain other EU countries
K Atikeler, G Ozcelikay
Value in Health 18 (7), A572, 2015
32015
Applicability of the EVIDEM multi-criteria decision analysis framework for orphan drugs Ñ results from a study in 7 Eurasian countries
A Baran-Kooiker, K Atikeler, K Gaitova, M Holownia-Voloskova, ...
Acta Poloniae Pharmaceutica 76 (3), 2019
22019
PND17 Comparing Cost of Therapeutic Plasma Exchange and Intravenous Immunoglobulin Infusion in Treating Guillain-BarrÉ Syndrome
K Atikeler, E Tuna, G Kockaya
Value in Health 15 (7), A548, 2012
22012
Health technology assessment in Türkiye: current status and perspectives on future implementation
EK Atikeler, AN Fasseeh, AK Mantel-Teeuwisse, Z Çalışkan, ZG Öner, ...
Health Policy and Technology 12 (1), 100701, 2023
12023
Comparison of The Reimbursement Decisions of Pharmaceuticals In Hungary, Romania And Turkey
K Atikeler, M Csanadi, M Subtirelu, A Baran, D Daneasa, AL Preda, ...
Value in Health 20 (9), A695, 2017
12017
Value of Life And Cost of Pre-Mature Deaths With The Perspective Of Productivity As Net Tax Revenue: A Comparison In Usa, Canada, Japan and Australia
FB Yenilmez, E Tuna, K Atikeler, G Kockaya, M Tatar
Value in Health 17 (7), A423, 2014
12014
Availability of risk sharing agreements in the Turkish pharmaceutical sector
E Tuna, M Tatar, G Ergin, A Senturk, K Atikeler
Value in Health 17 (7), A415, 2014
12014
Classification of Drugs Bringing from Abroad in Turkey According to Their Atc Codes
E Tuna, K Atikeler, Z Calýskan
Value in Health 17 (7), A788, 2014
12014
Cost of Obesity and Economic Value of Obesity Surgery for Turkey (CEVOS-T)
G Kockaya, M Tatar, G Ergin, K Atikeler
Value in Health 16 (7), A381, 2013
12013
Operational Cost of Obesity Surgery for Turkey
G Kockaya, G Ergin, K Atikeler, M Tatar, M Ozmen, M Gorgun, H Coskun, ...
12013
HPR119 Assessing Health Policies in Turkiye: Expert Insights on Current Challenges and Policy Recommendations from Written Motions
S Kahveci, EB Karahan, S Ileri, M Cansever, K Atikeler, B Kader, C Duran, ...
Value in Health 26 (12), S275, 2023
2023
EE318 Cost-Effectiveness Analysis for Soliqua in the Treatment of T2DM in Turkiye
K Atikeler, M Kurnaz, S Ileri, M Cansever, S Kahveci, B Kader, C Duran, ...
Value in Health 26 (12), S112, 2023
2023
The system can't perform the operation now. Try again later.
Articles 1–20